Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
MWN-AI** Summary
Cosmos Health Inc. (NASDAQ:COSM) has seen a significant increase in insider ownership as CEO Greg Siokas has acquired 1,466,764 shares valued at $526,000 over the past week. This purchase, made between April 21 and April 24, 2025, boosts Siokas's total holdings in the company to approximately 5.58 million shares. In the past five months, Siokas has invested over $1.3 million, acquiring a total of 2,777,469 shares, thus demonstrating his strong commitment to the company's mission.
Greg Siokas expressed pride in the company's progress, emphasizing his ongoing dedication to fostering value for shareholders. He highlighted that his total investment in Cosmos Health has surpassed $18 million since he began supporting the company. His recent transactions were documented in SEC filings, offering further details on his investment activity.
Cosmos Health operates as a diversified, vertically integrated global healthcare enterprise engaged in research and development, proprietary pharmaceuticals, and a range of healthcare products. Notably, the company has manufacturing capabilities through its subsidiary, Cana Laboratories S.A., which adheres to European GMP standards. Additionally, they are expanding their telehealth services through their acquisition of ZipDoctor, Inc.
With ongoing partnerships focused on addressing significant health issues like obesity, diabetes, and cancer—enhanced by innovative artificial intelligence technologies—Cosmos Health is poised for further expansion. The company has established a broad distribution network across Europe, Asia, and North America, with operations based in Greece and the UK.
Investors attentive to insider activity may view Siokas's significant stake as a positive indicator of the company's future potential, although they should consider the inherent risks associated with the healthcare sector and the broader market environment.
MWN-AI** Analysis
The recent stock acquisitions by Greg Siokas, CEO of Cosmos Health Inc. (NASDAQ:COSM), are a significant signal of confidence in the company’s future prospects. Over just a week, Siokas acquired 1,466,764 shares valued at approximately $526,000, adding to a cumulative total of 2,777,469 shares purchased over the past five months, representing an investment of about $1.3 million. This substantial buying activity, bringing his total stake to 5,582,066 shares, underscores his deep commitment to the company's mission and future growth potential.
From a market perspective, insider buying often suggests that management is optimistic about the company's trajectory, which can be attractive to investors. Siokas's investments, totaling over $18 million since inception, reinforce his belief in the scalability of Cosmos’s unique business model, which is diversified across pharmaceuticals, nutraceuticals, and telehealth services.
Analyzing the underlying business fundamentals, Cosmos Health is positioned to benefit from the growing demand for healthcare products and telehealth services in a post-COVID environment. Their focus on R&D, particularly in addressing major health concerns such as obesity, diabetes, and cancer through innovative technologies, further enhances their value proposition.
Investors should closely monitor the overall market sentiment towards healthcare stocks, along with broader economic factors that may impact market performance. Though potential volatility and risks exist, including regulatory challenges and global market uncertainties, Siokas's continued financial commitment suggests confidence that these can be navigated successfully.
In conclusion, prospective investors may view this as an opportune time to evaluate an entry point in Cosmos Health given the CEO's bullish stance, the company's robust portfolio, and its growth strategy in a dynamic healthcare landscape. However, due diligence is advised, considering the inherent risks associated with the sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025.
As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health.
Greg Siokas, CEO of Cosmos Health, stated: “Over the past five months alone, I have invested more than $1.3 million, increasing my ownership by over 2.7 million shares and bringing my total investment since inception to more than $18 million. I am proud of what we have accomplished in building a diversified, vertically integrated global health care company, and I am more excited than ever about the opportunities ahead. I remain deeply committed to supporting Cosmos and confident in our efforts to create value for our shareholders.”
Information on Mr. Siokas’s Recent Transactions:
Please refer to the filings on Form 4 filed with the SEC and available on the SEC's website for more information about the nature of the transactions, including details such as “Ownership Form”, “Transaction Date”, “Amount”, “Price”, and other relevant information regarding the shares acquired by Mr. Siokas.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com , www.skypremiumlife.com , www.cana.gr , www.zipdoctor.co , www.cloudscreen.gr , as well as LinkedIn and X .
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website ( www.sec.gov ). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
Disclaimer
This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a COSM financial position. COSM financial position and all other information regarding the featured Company should be verified directly with COSM. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in COSM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of COSM shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Compensation: Market Wire News and its affiliates has received six thousand dollars for Market Wire News advertising services from Relqo Media LLC for Brand Awareness Distribution, Corporate Communications, News, Press Release Enhancement and Social Media Solutions starting 2026-05-31 and ending 2026-06-05 provided by Market Wire News. To date, we have received a total of six thousand dollars. Please read our full disclaimer for compensation and more detailed information.
FAQ**
What strategic initiatives is Cosmos Holdings Inc. COSM pursuing to expand its presence in Europe and Asia following Greg Siokas's significant stock purchases?
How might the recent investment by CEO Greg Siokas in Cosmos Holdings Inc. COSM impact investor confidence and stock performance in the near term?
What role does R&D play in Cosmos Holdings Inc. COSM’s strategy to address major health disorders such as obesity and diabetes, especially with its AI drug repurposing technologies?
Given the uncertainties highlighted in the forward-looking statements, how does Cosmos Holdings Inc. COSM plan to mitigate potential risks related to financing and market conditions?
**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Health Inc. (NASDAQ: COSM).
NASDAQ: COSM
COSM Trading
2.67% G/L:
$0.2572 Last:
2,524,082 Volume:
$0.2525 Open:
